Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature.

by Nils Johan Fredriksson, Kerryn Elliott, Stefan Filges, Jimmy Van den Eynden, Anders Ståhlberg, Erik Larsson
Published 2017-05-01

Considerations and quality controls when analyzing cell-free tumor DNA

by Gustav Johansson, Daniel Andersson, Stefan Filges, Junrui Li, Andreas Muth, Tony E. Godfrey, Anders Ståhlberg
Published 2019-03-01

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

by Sara Bjursten, Christoffer Vannas, Stefan Filges, Florian Puls, Ankur Pandita, Henrik Fagman, Anders Ståhlberg, Max Levin
Published 2019-11-01

Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers.

by Kerryn Elliott, Martin Boström, Stefan Filges, Markus Lindberg, Jimmy Van den Eynden, Anders Ståhlberg, Anders R Clausen, Erik Larsson
Published 2018-12-01

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

by Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsén, Stefan Filges, Charlotta All-Eriksson, Bengt Andersson, Ana Carneiro, Hildur Helgadottir, Max Levin, Ingrid Ljuslinder, Roger Olofsson Bagge, Vasu R. Sah, Ulrika Stierner, Anders Ståhlberg, Gustav Ullenhag, Lisa M. Nilsson, Jonas A. Nilsson
Published 2021-08-01